Inflammatory myopathy following COVID-19 mRNA vaccination in a patient with VEXAS syndrome
Authors:
- Masakazu KakuraiMKMasakazu Kakurai
- Rie HondaRHRie Honda
- Naomi TsuchidaNTNaomi Tsuchida
- 1 October 2024
- journal article
- editorial
- Published by JLE in European Journal Of Dermatology
- Vol. 34 (5) , 545-546
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Spontaneous resolution of inflammatory myopathy involving the masseter muscle following COVID-19 mRNA vaccinationModern Rheumatology Case Reports, 2023
- COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protectionJournal of Biomedical Science, 2022
- Disorders of ubiquitylation: unchained inflammationNature Reviews Rheumatology, 2022
- Dermatomyositis-like rash and inflammatory myopathy after mRNA-1273 vaccinationRheumatology, 2022
- Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case ReportJournal of Korean Medical Science, 2022
- Covid-19–Associated Myopathy Caused by Type I InterferonopathyNew England Journal of Medicine, 2020
- Subcutaneous Sweet SyndromeDermatologic Clinics, 2008